This is Part I of our special report on the state of immunotherapy in the public markets. This report looks at promising anticancer immunotherapy technologies, and the major issues in bringing these technologies to the general public.
Browsing: Uncategorized
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
With the end of summer, conference season is upon us! Not OneMedForum, of course, which doesn’t kick off until “Biotech Week” in mid-January. But in New York, investors gathered for the autumn solstice at the BioCentury NewsMakers Conference early September in Times Square, and at the annual Rodman & Renshaw Global Investment Conference two days later. The two conferences were both well-attended, and the mood was just a little lighter, a little more buoyant, to suggest optimism. Insiders think we may have passed the nadir, and at a point of rejuvenation. Experts are pointing to several recent PDUFA date successes…
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
Defense Advanced Research Projects Agency, or DARPA, has awarded the Company a technology development contract worth up to $3.8 million over five years as part of its Dialysis-Like Therapeutics (DLT) program to treat sepsis, pending satisfactory achievement of key milestones.
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
OneMedForum New York 2012 will offer a diagnostics panel session on the afternoon of July 12th to discuss the rapid technological advances in diagnostics and personalized medicine.